Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.55 |
| ▸ | TYR | P14679 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063006 | 1.00 | ERN1 (0.55) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL2290188 | 0.85 | ALDH1A1 (0.59) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL9945980 | 0.84 | TYR (0.51) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL27645299 | 0.82 | TYR (0.46) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL7583964 | 0.82 | ALDH1A1 (0.44) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL4199940 | 0.81 | HDAC4 (0.43) | ERN1TYRALDH1A1HDAC4HDAC8 | |
| SCHEMBL7448262 | 0.81 | TYR (0.53) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL28804744 | 0.80 | ERN1 (0.53) | ERN1TYRALDH1A1TSHRKDM4E | |
| SCHEMBL7587589 | 0.80 | ERN1 (0.48) | ERN1ALDH1A1TSHRKDM4ETDP1 | |
| SCHEMBL29987643 | 0.80 | ERN1 (0.53) | ERN1TYRALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250214951-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | VASTHERA CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| CN-119095831-A | 3-Phenylisoxazole derivatives and pharmaceutical compositions for preventing or treating eye diseases containing the same as active ingredient | 瓦斯塞拉股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023182871-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | 바스테라 주식회사 | 2023-09-28 | — | — | WO | disclosed |
| US-11306084-B2 | Integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | Indalo Therapeutics, Inc. | 2019-11-14 | — | — | US | disclosed |
| EP-3562826-A1 | INTEGRIN ANTAGONISTS | Saint Louis University (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110177787-A | Integrin antagonists | 圣路易斯大学 | 2019-08-27 | — | — | CN | disclosed |
| WO-2018132268-A1 | INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-1994024081-A1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0591333-A1 | AZANORBORNANE DERIVATIVES. | PFIZER (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0587723-A1 | QUINUCLIDINE DERIVATIVES. | PFIZER (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5294744-A | Formylation process for aromatic aldehydes | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5294744-A | Formylation process for aromatic aldehydes | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993000330-A2 | AZANORBORNANE DERIVATIVES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| CN-1067428-A | QUINUCLIDINE DERIVATIVES | PFIZER (US) | 1992-12-30 | — | — | CN | disclosed |
| WO-1992021677-A1 | bibNUCLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1983000333-A1 | ANTI-HYPERTENSOR, HETEROCYCLICALLY DI-ORTHOSUBSTITUTED PHENOLS | TEULON, JEAN-MARIE | 1983-02-03 | — | — | WO | disclosed |
| EP-0070779-A2 | Di-ortho-substituted phenols of which one of the substitutions is a heterocycle, process for their preparation, anti-hypertensive medicines containing them and synthesis intermediates | CARPIBEM (CENTRE D'ACTIVITE ET DE RECHERCHE PHARMACEUTIQUE INDUSTRIELLE BIOLOGIQUE ET MEDICALE) Société Anonyme dite: (FR) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | ITGA5, ITGB5, ITGB2 | ERN1 4295/4885TYR 4259/4885ALDH1A1 749/4885 |
| US-20250214951-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | ATG7, BECN1, MAP1LC3B | ERN1 3296/4885TYR 187/4885ALDH1A1 336/4885 |
| US-11306084-B2 | Integrin antagonists | ITGA5, ITGB5, ITGB2 | ERN1 4295/4885TYR 4259/4885ALDH1A1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.